Medicine guide
Zynteglo
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Betibeglogene autotemcel
- Used in
- Blood, clotting and anaemia
- Made by
- bluebird bio (Netherlands) B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Zynteglo is indicated for the treatment of patients 12 years and older with transfusion-dependent β thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | bluebird bio (Netherlands) B.V. |
|---|---|
| Active substance | Betibeglogene autotemcel |
| Used in | Blood, clotting and anaemia |
| Classification | B06A · Blood, clotting and anaemia |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2019-05-29 |
| Last updated by the regulator | 2022-11-30 |
| EMA product number | EMEA/H/C/003691 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).